Real-world SEER registry analyses presented at ACMS and ASCO 2026 highlight how 31-GEP molecular testing identifies patients ...

The AJCC staging is based on three main characteristics defining the natural history of melanoma; namely the extent of the primary tumor (T), the absence or presence of regional lymph node metastasis ...

Using an evidence-based approach, revisions to the AJCC melanoma staging system have been made that reflect our improved understanding of this disease. These revisions will be formally incorporated ...

Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee ...

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk ...

Castle Biosciences, Inc. will present innovative research on cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 ASCO Annual Meeting in Chicago, showcasing findings from a collaboration with ...